R115777 in Treating Patients With Advanced Bladder Cancer

Phase 2 Completed H. Lee Moffitt Cancer Center and Research Institute National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder cancer.

Timeline

Start: 2000-03
Primary completion: —
Completion: 2005-05

Outcome

Missed primary endpoint

paper The objective response rate of R115777 was not sufficient to warrant future investigation in TCC as a single agent. PMID 15812833 ↗

Publications

Results Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15;103(10):2035-41. doi: 10.1002/cncr.21023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	300 mg	Oral